People with a PALB2 mutation who have been diagnosed with castration resistant prostate cancer could be eligible for PARP inhibitors therapy; although, in the largest study of people with inherited PALB2 mutations, the gene was linked to increased lifetime risk of breast cancer in women and men, ovarian and pancreatic cancer but not prostate cancer [22,23,24]. This evidence concerns the gene PARP1 and prostate carcinoma.